Image:
Sam Roberts of Cooke, Young and Keidan
The Covid-19 pandemic has, together with the rapid rise of medical technology and boom in M&A over the past couple of years, created something of a perfect storm for investment abuses in the medtech sector.
The pandemic itself has created an acute need for complex products with demanding levels of precision on a scale previously unknown - from antigen tests to monitoring equipment such as pulse oximeters,...
To continue reading this article...
Join Investment week
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
